2021年全球1型糖尿病发病率、患病率与死亡率及2040年预测:一项建模研究
该建模研究基于97个国家的1型糖尿病发病数据和37个国家的死亡数据,采用离散时间疾病-死亡模型估算2021年全球201个国家的1型糖尿病患病率、发病率、相关死亡率和预期寿命,并预测2040年患病病例。当年新诊断50万例(中位发病年龄39岁),约3.5万未诊断个体在有症状发作后12个月内死亡。
要点
- 2021年新诊断50万例,中位发病年龄39岁;约3.5万未诊断个体在有症状发作后12个月内死亡。
核心结论
- 2021年1型糖尿病负担巨大且预计将快速增加,尤其是在资源有限的国家。
- 大多数新发和现患病例为成人。
- 大量缺失的现患病例凸显了1型糖尿病的过早死亡以及挽救和延长1型糖尿病患者生命的机会。
- 新模型将作为Type 1 Diabetes Index模型公开提供,将成为支持1型糖尿病卫生服务、倡导和资助决策的重要工具。
研究设计与样本
- 研究拟合离散时间疾病-死亡模型(马尔可夫模型)以估算所有国家的1型糖尿病患病率、发病率、相关死亡率和预期寿命。
- 1型糖尿病发病和死亡数据分别来自97个和37个国家。
- 诊断率使用专家调查数据估算;死亡率使用已发表的1型糖尿病死亡数据的随机森林回归建模;预期寿命据此使用生命表计算。
- 估算结果对15个国家的观察患病率数据进行了验证。
- 研究还估算了缺失现患病例(即如果其死亡率与一般人群死亡率匹配,本应存活的额外1型糖尿病患者数)。
主要发现
- 2021年新诊断50万例(中位发病年龄39岁),约3.5万未诊断个体在有症状发作后12个月内死亡。
- 2021年确诊的10岁1型糖尿病患者的剩余预期寿命从低收入国家的平均13年至高收入国家的65年不等。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate data on type 1 diabetes prevalence, incidence, associated mortality and life expectancy are crucial to inform public health policy, but these data are scarce. We therefore developed a model based on available data to estimate these values for 201 countries for the year 2021 and estimate the projected prevalent cases in 2040. METHODS: We fitted a discrete-time illness-death model (Markov model) to data on type 1 diabetes incidence and type 1 diabetes-associated mortality to produce type 1 diabetes prevalence, incidence, associated mortality and life expectancy in all countries. Type 1 diabetes incidence and mortality data were available from 97 and 37 countries respectively. Diagnosis rates were estimated using data from an expert survey. Mortality was modelled using random-forest regression of published type 1 diabetes mortality data, and life expectancy was calculated accordingly using life tables. Estimates were validated against observed prevalence data for 15 countries. We also estimated missing prevalence (the number of additional people who would be alive with type 1 diabetes if their mortality matched general population rates). FINDINGS: In 2021, there were about 8·4 (95% uncertainty interval 8·1-8·8) million individuals worldwide with type 1 diabetes: of these 1·5 million (18%) were younger than 20 years, 5·4 million (64%) were aged 20-59 years, and 1·6 million (19%) were aged 60 years or older. In that year there were 0·5 million new cases diagnosed (median age of onset 39 years), about 35 000 non-diagnosed individuals died within 12 months of symptomatic onset. One fifth (1·8 million) of individuals with type 1 diabetes were in low-income and lower-middle-income countries. Remaining life expectancy of a 10-year-old diagnosed with type 1 diabetes in 2021 ranged from a mean of 13 years in low-income countries to 65 years in high-income countries. Missing prevalent cases in 2021 were estimated at 3·7 million. In 2040, we predict an increase in prevalent cases to 13·5-17·4 million (60-107% higher than in 2021) with the largest relative increase versus 2021 in low-income and lower-middle-income countries. INTERPRETATION: The burden of type 1 diabetes in 2021 is vast and is expected to increase rapidly, especially in resource-limited countries. Most incident and prevalent cases are adults. The substantial missing prevalence highlights the premature mortality of type 1 diabetes and an opportunity to save and extend lives of people with type 1 diabetes. Our new model, which will be made publicly available as the Type 1 Diabetes Index model, will be an important tool to support health delivery, advocacy, and funding decisions for type 1 diabetes. FUNDING: JDRF International.
引用
- Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022. PMID: 36113507. doi:10.1016/S2213-8587(22)00218-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。